gout, nonalcoholic fatty liver disease, enterosorbent, treatment


Background. Gout is still one of the major health problems despite significant advances in treatment in recent years. It has been proved that pathogenetic mechanisms of development and progression of gout are associated with nonalcoholic fatty liver disease. Complex pathogenic treatment of patients aimed at different parts of the pathological process has recently been supplemented with the enterosorbents.

Objective. The aim of the research is to study the clinical features of gout with concomitant nonalcoholic fatty liver disease (NAFLD) and to evaluate the effect of carbon enterosorbent on its course.

Methods. 123 patients were involved in the study. They were divided into 2 groups: group 1 included patients with gout without liver damage, and group 2 included patients with concomitant NAFLD. Each of these groups was divided into subgroups, in which the patients received carbon enterosorbent carboline plus basic treatment. The control group consisted of 30 healthy persons. Anamnesis, physical examination, uric acid (UA), C-reactive protein (CRP) content, erythrocyte sedimentation rate (ESR) in serum were determined. Gout activity was evaluated using the Gout Activity Score (GAS).

Results. Basic treatment in combination with carbon enterosorbent contributed to faster cure of intoxication, pain and joint syndromes, as well as decrease of the inflammatory process activity.

Conclusions. The course of gout in the patients with concomitant NAFLD is more severe. Adding of carbon granular enterosorbent carboline in the complex treatment of patients with gout with or without concomitant NAFLD in the exacerbation phase contributes to a faster cureing dynamics of clinical and laboratory manifestations of the disease.

Author Biography


Ph.D. student, Department of Internal Medicine Propedeutics and Phthisiology of I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine


Herasymenko SI, Poluliakh MV, Duda MS, Pshenychnyi TIe. Current aspects of conservative treatment of acute gouty arthritis. Chronicle of traumatology and orthopedics. 2013;1-2:204-7.

Orlova IV. Influence of disease activity on quality of life of patients with gout. Ukrainian Journal of Medicine, Biology and Sport. 2018;3(5):127–31.

doi: 10.26693/jmbs03.05.127

Aung T, Myung G, FitzGerald JD. Treatment approaches and adherence to urate-lowering therapy for patients with gout. Patient Prefer Adherence. 2017;11:795–800.


Edwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011;14(1):10-5.

doi: 10.3111/13696998.2010.540874

Svintsitskyi AS. Current views on the diagnosis and treatment of gout. Health of Ukraine. Rheu­ma­tolog. 2013 February: 70-2.

Barskova VG, Eliseev MS, Denisov IS, Elisee­va ME, Belikov OA, Fadienko GR, i dr. The frequency of metabolic syndrome and concomitant diseases in patients with gout. Data from a multicenter study. Scientific and Practical Rheumatology. 2012;6(50):15-8.

Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on pre­valence and treatment options. BMC Med. 2017; 15(1): 123.


Skliarov YeYa., Aksentiichuk KhB., Kurliak NV. Monitoring of liver function disorders in patients with non-alcoholic fatty liver disease on the background of metabolic syndrome. Hepatology. 2015;1: 34-41.

Tkachuk SO, Bashta HV, Lapovets LIe, Zalets­kyi MP. Changes in carbohydrate and lipid metabolism and C-reactive protein in patients with coronary heart disease and fatty hepatosis. Medical and Clinical Chemistry. 2016;18(4):29-33.

doi: 10.11603/mcch.2410-681X.2016.v0.i4.7252

Kondratiuk VIe, Tarasenko OM. Hyperuricemia and gout: the current state of the problem. Ukrainian Rheumatology Journal. 2016;3:30–7.

Scirè C, Carrara G, Viroli C, Cimmino M, Taylor W, Manara M, et al. Development and First Validation of a Disease Activity Score for Gout. Arthritis Care & Research. 2016; 68 (10): 1530-7.

doi: 10.1002/acr.22844

Abrahamovych OO, Faiura OP, Abrahamo­vych UO. Comorbidity: a modern perspective on the problem; classification (message second). Lviv Clinical Bulletin. 2016;1:31-9.

Svintsitskyy AS, Kozak NP, Ostafiichuk AS. Pecularities of gouts’ course in association with the metabolic syndrome. Ukrainian Rheumatology Journal. 2011;4:46.

Younossi ZM. Non-alcoholic fatty liver disease – a global public health perspective. J. Hepatol. 2019;70(3):531-44.

doi: 10.1016/j.jhep.2018.10.033

Pillinger MH, Goldfarb DS, Keenan RT. Gout and its comorbidities. Bull NYU Hosp Jt Dis. 2010;68(3):199-203.

Orlovsky VF, Murenets NO. Chronic inflam­mation in nonalcoholic fatty liver disease. Pathologia. 2010;7(3):99-102.

Svіntsіtskiy AS. Diagnosis and treatment of rheumatic diseases: manual. Kiev: The Publishing House of the Medknyga; 2017. 372 р.




How to Cite

Mudra, U. O. (2020). GOUT AND NONALCOHOLIC FATTY LIVER DISEASE: EFFECT OF ENTEROSORPTION’S ADDITION TO COMMON TREATMENT. International Journal of Medicine and Medical Research, 5(2), 40–46. https://doi.org/10.11603/ijmmr.2413-6077.2019.2.10886